Related references
Note: Only part of the references are listed.Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
Noopur S Raje et al.
Lancet Haematology (2022)
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Cristina Encinas et al.
BLOOD CANCER JOURNAL (2022)
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Hartmut Goldschmidt et al.
Lancet Haematology (2022)
Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial
Hartmut Goldschmidt et al.
BLOOD (2021)
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. A. Dimopoulos et al.
ANNALS OF ONCOLOGY (2021)
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
Thierry Facon et al.
LEUKEMIA (2020)
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
Hartmut Goldschmidt et al.
LEUKEMIA (2020)
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Michele Cavo et al.
LANCET HAEMATOLOGY (2020)
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma
Elias K. Mai et al.
LEUKEMIA (2019)
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
Hans Salwender et al.
BMC CANCER (2019)
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
Mark T. Drayson et al.
LANCET ONCOLOGY (2019)
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial
H. Goldschmidt et al.
LEUKEMIA (2018)
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis
Sara Bringhen et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival
Ingemar Turesson et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
Charles Dumontet et al.
LEUKEMIA (2018)
Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis
Li Ying et al.
ONCOTARGET (2017)
Recognition of early mortality in multiple myeloma by a prediction matrix
Howard Terebelo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis
Benjamin W. Teh et al.
EUROPEAN JOURNAL OF CANCER (2016)
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Antonio Palumbo et al.
BLOOD (2015)
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma
E. K. Mai et al.
LEUKEMIA (2015)
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
Cecilie Blimark et al.
HAEMATOLOGICA (2015)
mice: Multivariate Imputation by Chained Equations inR
Stef van Buuren et al.
Journal of Statistical Software (2015)
Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression-Related Death
Philippe Moreau et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S. K. Kumar et al.
LEUKEMIA (2014)
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial
Pieter Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
Infections in Patients with Multiple Myeloma in the Era of High-Dose Therapy and Novel Agents
Marcio Nucci et al.
CLINICAL INFECTIOUS DISEASES (2009)
Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party
BM Augustson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
